Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

thinkemotive

- PMLiVE

NICE rejects Novartis migraine treatment Aimovig

A draft 'no' to first-in-class treatment, despite discount

- PMLiVE

Nektar confirms BMS deal for NKTR-214 is on track

Shares in Nektar rose 10% in the wake of the presentation at JPM healthcare conference

- PMLiVE

EMA sees approval numbers rise in 2018

Agency faces Brexit test in 2019

- PMLiVE

Moderna CEO makes case for firm’s lofty valuation

mRNA specialist has to convince investors after stocks slide

Joint working that works

Dovetail

Q&A with Dr Timothy Vollmer, leading MS Neurologist

Blue Latitude Health sits down with key opinion leader and specialist neurologist Dr Timothy Vollmer to better understand the paradigm shift in MS treatment. He explains the challenges neurologists face...

Blue Latitude Health

- PMLiVE

Novartis gets breakthrough tag from FDA for sickle cell drug

Latest pipeline therapy for painful blood disorder

- PMLiVE

NHS Long-term Plan welcomed – but warnings on staff and overpromising

New emphasis on prevention, integrated healthcare and digital services

- PMLiVE

AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief

Underlines importance of cancer drugs to company's future growth

- PMLiVE

Merck’s backing of NGM Bio yields NASH drug deal

Drug has potential in diabetes treatment as well

Eli Lilly HQ

Lilly adds to pharma M&A run with $8bn Loxo buy-out

Lilly claims company ahead of more dominant oncology players

- PMLiVE

BMS and Celgene deal sparks debate on pharma profit motive, more M&A

Biopharma backlash at Warren tweet, but Celgene tactics in the spotlight

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links